It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
T cell development requires the coordinated rearrangement of T cell receptor (TCR) gene segments and the expression of either αβ or γδ TCR. However, whether and how de novo synthesis of nutrients contributes to thymocyte commitment to either lineage remains unclear. Here, we find that T cell-specific deficiency in glutamine:fructose-6-phosphate aminotransferase 1 (GFAT1), the rate-limiting enzyme of the de novo hexosamine biosynthesis pathway (dn-HBP), attenuates hexosamine levels, blunts N-glycosylation of TCRβ chains, reduces surface expression of key developmental receptors, thus impairing αβ-T cell ontogeny. GFAT1 deficiency triggers defects in N-glycans, increases the unfolded protein response, and elevates γδ-T cell numbers despite reducing γδ-TCR diversity. Enhancing TCR expression or PI3K/Akt signaling does not reverse developmental defects. Instead, dietary supplementation with the salvage metabolite, glucosamine, and an α-ketoglutarate analogue partially restores αβ-T cell development in GFAT1T-/- mice, while fully rescuing it in ex vivo fetal thymic organ cultures. Thus, dn-HBP fulfils, while salvage nutrients partially satisfy, the elevated demand for hexosamines during early T cell development.
Although T cell commitment to specific lineages coincides with the rearrangement of T cell receptor loci, it remains unclear whether metabolism also influences this process. Here, authors show that de novo hexosamine biosynthesis promotes αβ T cell lineage commitment and γδ-TCR diversity and can be modulated by dietary supplementation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 The State Univ. of New Jersey, Department of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers, Piscataway, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796)
2 The State Univ. of New Jersey, Dept. of Pharmacology and Pediatrics, Robert Wood Johnson Medical School, and Rutgers Cancer Institute of New Jersey, Rutgers, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796); University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, USA (GRID:grid.26790.3a) (ISNI:0000 0004 1936 8606)
3 The State Univ. of New Jersey, Dept. of Pharmacology and Pediatrics, Robert Wood Johnson Medical School, and Rutgers Cancer Institute of New Jersey, Rutgers, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796)
4 The State Univ. of New Jersey, Dept. of Medicine, Div. of Endocrinology, Child Health Inst. of New Jersey, Rutgers, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796)